The prevalence of cardiovascular risk factors in male patients who have lower urinary tract symptoms

Objectives To assess the prevalence of cardiovascular risk factors in men presenting with lower urinary tract symptoms, and their possible correlation with the severity of such symptoms.

Design Retrospective cohort study.

Setting Specialty clinic, Hong Kong.

Patients A total of 617 men presenting with lower urinary tract symptoms between April 2005 and October 2006.

Main outcome measures Presence of cardiovascular risk factors inferred from the prior and current medical and social history as well as physical examination and investigative findings, among patients with International Prostatic Symptom Scores of different severity.

Results Of 617 patients, 268 (43%) had known hypertension and 318 (52%) had a history of smoking. According to the World Health Organization criteria for Asian populations, 396 (64%) patients were considered to be overweight (body mass index ≥23 kg/m²). A total of 178 (29%) patients were either known to have or were diagnosed to have dysglycaemia during workup. For dyslipidaemia and hyperuricaemia, the corresponding figures were 331 (54%) and 191 (31%). In total, 264 (43%) patients were newly diagnosed as having dysglycaemia, dyslipidaemia, or hyperuricaemia. Logistic regression indicated that only hyperuricaemia and a smoking history were significant predictors of moderate-to-severe lower urinary tract symptoms (International Prostatic Symptom Score ≥8), with respective adjusted odds ratios of 2.20 (95% confidence interval, 1.12-4.31; P=0.022) and 2.11 (1.24-3.57, P=0.006). Patients with moderate-to-severe International Prostatic Symptom Scores had a statistically higher chance of having at least one cardiovascular risk factor during assessment (P=0.001).

Conclusions Cardiovascular risk factors were prevalent in male patients who had lower urinary tract symptoms; a large portion of these cardiovascular risk factors were not recognised until their urological consultations. Patients with moderate-to-severe lower urinary tract symptoms (International Prostatic Symptom Score ≥8) had statistically higher chances of having more cardiovascular risk factors.

Introduction
Cardiovascular disease is one of the leading causes of non-cancer death in adults. Although advances in medicine have decreased the related mortality,1,2 prevention is still the best approach.3 Early interventions to combat risk factors have proved effective in decreasing both the incidence of and mortality from cardiovascular disease.4,5 However, the well-recognised reluctance of men to seek health care is a major obstacle to the early recognition and management of such risks. Nonetheless, when men do seek medical advice, they frequently present with urological symptoms, and it is suggested that urologists can play a key role in men’s overall health.6 Hence, in April 2005 we initiated a screening programme for cardiovascular risk factors in patients presenting with lower urinary tract symptoms (LUTS). The aims of this study were to assess the prevalence of those factors in our patients, and to evaluate any correlation between them and the severity of LUTS.
### Patients and methods

Male patients who presented with LUTS to our urology unit from April 2005 to October 2006 were included in the study. All the patients were subjected to comprehensive assessments that included the following:

1. Detailed history of LUTS and other urological symptoms;
2. Medical history, with particular attention to previous cardiovascular diseases and metabolic disorders such as diabetes mellitus, hypertension, dyslipidaemia, etc;
3. Smoking history: non-smoker, current smoker, or ex-smoker;
4. Physical examination, including the assessment of body weight, height, body mass index (BMI), blood pressure, and digital rectal examination;
5. International Prostatic Symptom Score (IPSS), uroflowmetry, and post-void residual urine for the assessment of LUTS;
6. Blood laboratory examination: renal function tests and fasting plasma glucose, urate and lipid profiles;
7. Mid-stream urine for microscopy and culture; and
8. Plain abdominal radiography.

The information from these assessments was prospectively added to a computer database.

The cardiovascular risk factors selected for evaluation included: history of smoking (to determine whether the patient was currently a smoker or had ceased smoking during assessment), being overweight, and having hypertension, dysglycaemia, dyslipidaemia or hyperuricaemia. In line with the World Health Organization (WHO) expert consultation on the appropriate BMI for Asian populations, patients were classified as overweight if their BMI was greater than 23 kg/m². The diagnosis of hypertension was based on a self-reporting system. Dysglycaemia was defined as the patient having a history of diabetes mellitus, or a fasting plasma glucose level of 6.1 mmol/L or higher. The reference levels for plasma high-density lipoprotein–cholesterol (HDL-cholesterol) and low-density lipoprotein–cholesterol (LDL-cholesterol) were defined in line with the findings of the National Cholesterol Education Program Expert Panel on Detection, Evaluation And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Hyperuricaemia was defined as a fasting plasma urate level of greater than 0.43 mmol/L, based on a local laboratory reference range.

### Statistical analysis

All of the results were expressed as means, standard deviations (SDs), medians, or percentages as appropriate. Chi squared tests followed by logistic regression analysis were used to assess associations between the cardiovascular risk factors and the proportion of patients with moderate-to-severe IPSS as well as to assess the correlation of LUTS severity (mild symptoms vs moderate-to-severe symptoms) with the number of risk factors present. A two-tailed P value of <0.05 was used to assess statistical significance. We performed the statistical analysis with the Statistical Package for the Social Sciences (Windows version 14.0; SPSS Inc, Chicago [IL], US).

### Results

We assessed 617 male patients in our clinic during the study period. Their mean age was 65.4 (range, 39-94) years. Table 1 shows the IPSS symptom severity distribution according to age and prostate size. The IPSS was stratified into mild (0-7), moderate-to-severe (≥8); 11% of patients were in the mild category, and 89% in the moderate-to-severe category. The overall mean and median prostate sizes of the patients (as determined by digital rectal examination) were
Cardiovascular risk factors and lower urinary tract symptom

Hong Kong Med J Vol 13 No 6 December 2007 www.hkmj.org 423

36.4 mL and 35.0 mL, respectively (SD, 9.6 mL; range, 20-100 mL). Respective mean and median prostate sizes for patients with mild symptoms were 37.2 mL and 35.0 mL, and the corresponding values for those with moderate-to-severe symptoms were 36.3 mL and 35.0 mL. There was no statistically significant difference between the means of the two groups (P=0.5).

Among these patients, 84 (14%) were smokers, 234 (38%) were ex-smokers, and 299 (48%) were non-smokers. Ischaemic heart disease affected 44 (7%) patients, and cerebrovascular disease affected 34 (6%) patients. There was a known history of hypertension in 268 (43%) patients. Patient numbers with known diabetes, dyslipidaemia, and hyperuricaemia were 105 (17%), 96 (16%), and 30 (5%), respectively.

As shown in Table 2, the mean BMI was 24.1 kg/m² (range, 15.4-33.8 kg/m²). According to the WHO criteria for Asian populations, 396 (64%) patients were regarded as overweight (BMI ≥23 kg/m²) and 231 (37%) as obese (BMI ≥25 kg/m²).

A total of 153 (25%) of the patients had elevated fasting plasma sugar levels. Moreover, 117 (19%) had elevated fasting triglyceride, and 231 (37%) had elevated fasting LDL-cholesterol levels, whilst 62 (10%) had low fasting HDL-cholesterol. Table 3 shows that 178 (29%) of the patients had either a known history of dysglycaemia or were diagnosed during workup. Similarly, known or diagnosed dyslipidaemia was encountered in 331 (54%) and hyperuricaemia in 191 (31%) patients. In total, 264 (43%) of them were newly diagnosed as having dysglycaemia, dyslipidaemia, or hyperuricaemia.

Table 4 lists the prevalence of cardiovascular risk factors in these patients. In our univariate analysis, a history of smoking and a diagnosis of

**TABLE 1. Distribution of symptom severity according to age and prostate size**

<table>
<thead>
<tr>
<th>Age</th>
<th>Mild LUTS (IPSS ≤7)*</th>
<th>Moderate-to-severe LUTS (IPSS ≥8)</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD, range)</td>
<td>64.8 (11.9; 42-92)</td>
<td>65.5 (10.1; 39-94)</td>
</tr>
<tr>
<td>&lt;50</td>
<td>7 (10%)</td>
<td>33 (6%)</td>
<td>40 (6%)</td>
</tr>
<tr>
<td>50-59</td>
<td>18 (26%)</td>
<td>129 (24%)</td>
<td>147 (24%)</td>
</tr>
<tr>
<td>60-69</td>
<td>19 (28%)</td>
<td>194 (35%)</td>
<td>213 (35%)</td>
</tr>
<tr>
<td>70-79</td>
<td>18 (26%)</td>
<td>146 (27%)</td>
<td>164 (27%)</td>
</tr>
<tr>
<td>≥80</td>
<td>7 (10%)</td>
<td>46 (8%)</td>
<td>53 (9%)</td>
</tr>
<tr>
<td>Overall</td>
<td>69 (11%)</td>
<td>548 (99%)</td>
<td>617 (100%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prostate size (mL)</th>
<th>Mean</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild LUTS (IPSS ≤7)*</td>
<td>37.2</td>
<td>35.0</td>
</tr>
<tr>
<td>Moderate-to-severe LUTS (IPSS ≥8)</td>
<td>36.3</td>
<td>35.0</td>
</tr>
<tr>
<td>Overall</td>
<td>36.4</td>
<td>35.0</td>
</tr>
</tbody>
</table>

* LUTS denotes lower urinary tract symptoms, and IPSS International Prostatic Symptom Score

**TABLE 2. Overall distribution of body mass index (BMI) according to symptom severity**

<table>
<thead>
<tr>
<th>BMI (kg/m²)</th>
<th>Overall</th>
<th>Mild LUTS (IPSS ≤7)*</th>
<th>Moderate-to-severe LUTS (IPSS ≥8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group</td>
<td>Cumulative</td>
<td>Group</td>
<td>Cumulative</td>
</tr>
<tr>
<td>Mean (SD, range)</td>
<td>24.1 (3.2, 15.4-33.8)</td>
<td>23.6 (3.3, 16.4-31.7)</td>
<td>24.1 (3.2, 15.4-33.8)</td>
</tr>
<tr>
<td>BMI group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;23.00</td>
<td>221 (36%)</td>
<td>221 (36%)</td>
<td>30 (44%)</td>
</tr>
<tr>
<td>23.00-24.99</td>
<td>165 (27%)</td>
<td>386 (63%)</td>
<td>16 (23%)</td>
</tr>
<tr>
<td>25.00-27.49</td>
<td>149 (24%)</td>
<td>535 (87%)</td>
<td>16 (23%)</td>
</tr>
<tr>
<td>27.50-29.99</td>
<td>55 (9%)</td>
<td>590 (96%)</td>
<td>3 (4%)</td>
</tr>
<tr>
<td>≥30.00</td>
<td>27 (4%)</td>
<td>617 (100%)</td>
<td>4 (6%)</td>
</tr>
</tbody>
</table>

* LUTS denotes lower urinary tract symptoms, and IPSS International Prostatic Symptom Score

**TABLE 3. Patient numbers with known and newly diagnosed dysglycaemia, dyslipidaemia, and hyperuricaemia**

<table>
<thead>
<tr>
<th></th>
<th>Known</th>
<th>Newly diagnosed</th>
<th>Known + newly diagnosed</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysglycaemia</td>
<td>105 (17%)</td>
<td>73 (12%)</td>
<td>155 (25%)</td>
<td>178 (29%)</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>96 (16%)</td>
<td>235 (38%)</td>
<td>321 (52%)</td>
<td>331 (54%)</td>
</tr>
<tr>
<td>Hyperuricaemia</td>
<td>30 (5%)</td>
<td>161 (26%)</td>
<td>175 (28%)</td>
<td>191 (31%)</td>
</tr>
</tbody>
</table>

Hong Kong Med J Vol 13 No 6 December 2007 www.hkmj.org 423
multivariate analysis revealed similar results, with an adjusted odds ratio of 2.20 (95% CI, 1.12-4.31; P=0.022) for the association between moderate-to-severe LUTS and hyperuricaemia, and 2.11 (95% CI, 1.24-3.57; P=0.006) for that between moderate-to-severe LUTS and smoking. Table 5 lists the distribution of patients and the mean prostate size with different numbers of risk factors. No correlation was noted between the mean prostate size and the number of risk factors.

Table 6 illustrates that patients with moderate-to-severe IPSSs had a higher chance of having at least one cardiovascular risk factor during assessment (P=0.001).

Discussion

We found a very high level of risk from cardiovascular disease in our patients. Our results show that 530 (86%) of the 617 patients had at least one such risk factor, of which about half (264 or 50%) were diagnosed as having dyslipidaemia, dysglycaemia, or hyperuricaemia during the urological workup. Patients with moderate-to-severe as opposed to mild IPSSs had a significantly higher chance of having at least one cardiovascular risk factor during assessment (P=0.001).
least one cardiovascular risk factor.

Cardiovascular disease is one of the leading causes of non-cancer death in adult males. Although better management of ischaemic heart disease, heart failure, and stroke has significantly improved patient outcomes, prevention is still the best approach to minimising the morbidity and mortality of these conditions.\textsuperscript{3,4,14} The identification of risk factors for cardiovascular disease with subsequent modification is the mainstay of primary prevention.\textsuperscript{3-8}

The fact that men under-use the health care systems\textsuperscript{9,16} probably accounts for the higher risk they face compared to females and their higher morbidity and mortality from a variety of individual diseases.\textsuperscript{17,18} The common barriers to health care advice that men face include personal concepts of traditional male social roles, and the systemic barriers they encounter in relation to time and ease of access.\textsuperscript{16} Yet this situation could be resolved by influencing individual behaviour or modifying health care services to more easily suit the ‘average’ man.\textsuperscript{19}

As urological symptoms are among the most common for which men seek medical advice, physicians managing these problems (in primary care or as specialists) have the opportunity to actively promote their general health. Other evidence indicates cardiovascular risk factors are closely related to LUTS. Although such studies have mainly assessed the relationship in either asymptomatic populations or those recruited by health surveys,\textsuperscript{20-21} our cohort comprised male patients who presented with symptomatic voiding problems.

In our symptomatic population, the prevalence of cardiovascular risk factors was higher than that reported in previous studies, with more than 85% of patients having at least one cardiovascular risk factor during assessment. Among latter, about half were not known to have that risk factor before their consultations. Despite this ‘skewed’ population, we still noted an association between symptom severity and cardiovascular risk factors. This in itself shows that urological consultation can provide an effective means of screening for cardiovascular risk factors in males with LUTS, especially those with moderate-to-severe symptoms.

Our multivariate analysis revealed that both smoking and hyperuricaemia were significant predictors of moderate-to-severe LUTS. Smoking is a well-documented factor related to the severity of LUTS,\textsuperscript{20,22} but we are the first to report the association with hyperuricaemia. As hyperuricaemia is increasingly recognised as an important cardiovascular risk factor,\textsuperscript{11,12} awareness of its possible relationship with LUTS may help to improve the management of both conditions.

<table>
<thead>
<tr>
<th>IPSS</th>
<th>Risk factor=0</th>
<th>Risk factor ≥1</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>19 (28%)</td>
<td>50 (72%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Moderate-to-severe</td>
<td>68 (12%)</td>
<td>480 (88%)</td>
<td></td>
</tr>
</tbody>
</table>

The one cardiovascular risk factor we recorded that could limit the generalisability of our findings is hypertension. Given the limitations of our clinical setting, we could not take repeated measurements of blood pressure over time.\textsuperscript{23} Hence, only those who presented with a known history of hypertension were labelled as having it. This could have underestimated the overall incidence of hypertension in our population.

The underlying mechanism for the association of cardiovascular risk factors and LUTS is still unknown. There was a report suggesting that these risk factors correlated with prostate size,\textsuperscript{24} possibly related to increased production of growth factors secondary to hypoxia induced by vascular damage.\textsuperscript{25} However, we did not observe any correlation between prostate size with either the severity of LUTS or the number of cardiovascular risk factors. As we used digital rectal examination to estimate the size of the prostate, our estimates might not be very accurate. Further studies to overcome this challenge may be helpful.

Keeping in mind the need to improve men’s responsiveness to health care, primary care physicians and urologists should consider the broader picture when treating patients with erectile or other sexual dysfunction. In fact, erectile dysfunction is regarded as an early sign of endothelial dysfunction,\textsuperscript{26,27} and a significant proportion of patients with such symptoms later develop cardiovascular disease.\textsuperscript{28} To broaden perspectives still further, physicians should deliver advice on matters such as diet, alcohol, or substance consumption, and regular physical activity, whenever they are consulted by male patients. This also extends to appropriate advice about prostate cancer screening. With a view to improving attitudes toward better health care among men, physicians should play a more active role whenever they can.

**Conclusions**

Cardiovascular risk factors were prevalent in our male patients suffering from LUTS; a large proportion of the prevailing cardiovascular risk factors were unknown before the urological consultation. Comprehensive medical screening should be considered for all such patients, especially those with moderate-to-severe LUTS. Subsequent medical advice and lifestyle modification may be beneficial to the overall health of these patients, and to men in general.
References


